Serum proteomics and biomarkers in hepatocellular carcinoma and chronic liver disease

Clinical Cancer Research

Volumn 14, Issue 2, 2008, Pages 470-477

  Zinkin, Noah T ^a   Grall, Franck ^a   Bhaskar, Killimangalam ^a   Otu, Hasan H ^a   Spentzos, Dimitrios ^a   Kalmowitz, Brett ^a   Wells, Meghan ^a   Guerrero, Manuel ^a   Asara, John M ^a   Libermann, Towia A ^a   Afdhal, Nezam H ^a,b  

^a HARVARD MEDICAL SCHOOL   (United States)

^b HARVARD INSTITUTES OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AGGLUTININ; ALPHA FETOPROTEIN; BIOLOGICAL MARKER; PROTHROMBIN;

ADULT; AGED; ARTICLE; CANCER DIAGNOSIS; CHRONIC LIVER DISEASE; CLINICAL ARTICLE; CONTROLLED STUDY; FEMALE; HEPATITIS C; HUMAN; LENTIL; LIVER CELL CARCINOMA; LIVER CIRRHOSIS; MALE; PRIORITY JOURNAL; PROTEIN MICROARRAY; PROTEOMICS; SENSITIVITY AND SPECIFICITY; SURFACE ENHANCED LASER DESORPTION IONIZATION TIME OF FLIGHT MASS SPECTROMETRY; TUMOR VOLUME;

ADULT; AGED; AGED, 80 AND OVER; ALPHA-FETOPROTEINS; CARCINOMA, HEPATOCELLULAR; CYSTATINS; FEMALE; HEPATITIS C, CHRONIC; HUMANS; LIVER CIRRHOSIS; LIVER NEOPLASMS; MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS; PROTEOMICS; SENSITIVITY AND SPECIFICITY; SPECTROMETRY, MASS, MATRIX-ASSISTED LASER DESORPTION-IONIZATION; TUMOR MARKERS, BIOLOGICAL;

EID: 38949145743     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-07-0586     Document Type: Article

References (39)

1. Di Bisceglie AM. Hepatitis C and hepatocellular carcinoma. Hepatology 1997;26:34-8S.
2. El-Serag HB, Mason AC. Rising incidence of hepatocellular carcinoma in the United States. N Engl J Med 1999;340:745-50.
3. El-Serag HB. Hepatocellular carcinoma and hepatitis Cin the United States. Hepatology 2002;36:S74-83.
4. Bruix J, Llovet JM. Prognostic prediction and treatment strategy in hepatocellular carcinoma. Hepatology 2002;35:519-24.
5. Fattovich G, Giustina G, Degos F, et al. Morbidity and mortality in compensated cirrhosis type C: a retrospective follow-up study of 384 patients. Gastroenterology 1997;112:463-72.
6. Hoofnagle JH. Course and outcome of hepatitis C. Hepatology 2002;36:S21-9.
7. Seeff LB, Buskell-Bales Z, Wright EC, et al. Long-term mortality after transfusion-associated non-A, non-B hepatitis. The National Heart, Lung, and Blood Institute Study Group. N Engl J Med 1992;327:1906-11.
8. Tong MJ, el-Farra NS, Reikes AR, Co RL. Clinical outcomes after transfusion-associated hepatitis C. N Engl J Med 1995;332:1463-6.
9. Gebo KA, Chander G, Jenckes MW, et al. Screening tests for hepatocellular carcinoma in patients with chronic hepatitis C: a systematic review. Hepatology 2002;36:S84-92.
10. Sherman M. α-Fetoprotein: an obituary. J Hepatol 2001;34:603-5.
11. Daniele B, Bencivenga A, Megna AS, Tinessa V. α-Fetoprotein and ultrasonography screening for hepatocellular carcinoma. Gastroenterology 2004;127:S108-12.
12. Bayati N, Silverman AL, Gordon SC. Serum α-fetoprotein levels and liver histology in patients with chronic hepatitis C. Am J Gastroenterol 1998;93:2452-6.
13. Goldstein NS, Blue DE, Hankin R, et al. Serum α-fetoprotein levels in patients with chronic hepatitis C. Relationships with serum alanine aminotransferase values, histologic activity index, and hepatocyte MIB-1 scores. Am J Clin Pathol 1999;111:811-6.
14. Di Bisceglie AM, Sterling RK, Chung RT, et al. Serum α-fetoprotein levels in patients with advanced hepatitis C: results from the HALT-C Trial. J Hepatol 2005;43:434-41.
15. Rapaccini GL, Pompili M, Caturelli E, et al. Hepatocellular carcinomas <2 cm in diameter complicating cirrhosis: ultrasound and clinical features in 153 consecutive patients. Liver Int 2004;24:124-30.
16. Bruix J, Sherman M. Management of hepatocellular carcinoma. Hepatology 2005;42:1208-36.
17. Shiraki K, Takase K, Tameda Y, Hamada M, Kosaka Y, Nakano T. A clinical study of lectin-reactive α-fetoprotein as an early indicator of hepatocellular carcinoma in the follow-up of cirrhotic patients. Hepatology 1995;22:802-7.
18. Sato Y, Nakata K, Kato Y, et al. Early recognition of hepatocellular carcinoma based on altered profiles of α-fetoprotein. N Engl J Med 1993;328:1802-6.
19. Wang SS, Lu RH, Lee FY, et al. Utility of lentil lectin affinity of α-fetoprotein in the diagnosis of hepatocellular carcinoma. J Hepatol 1996;25:166-71.
20. Izuno K, Fujiyama S, Yamasaki K, Sato M, Sato T. Early detection of hepatocellular carcinoma associated with cirrhosis by combined assay of des-γ-carboxy prothrombin and α-fetoprotein: a prospective study. Hepatogastroenterology 1995;42:387-93.
21. Ikoma J, Kaito M, Ishihara T, et al. Early diagnosis of hepatocellular carcinoma using a sensitive assay for serum des-γ-carboxy prothrombin: a prospective study. Hepatogastroenterology 2002;49:235-8.
22. Ishii M, Gama H, Chida N, et al. Simultaneous measurements of serum α-fetoprotein and protein induced by vitamin K absence for detecting hepatocellular carcinoma. South Tohoku District Study Group. Am J Gastroenterol 2000;95:1036-40.
23. Shimauchi Y, Tanaka M, Kuromatsu R, et al. A simultaneous monitoring of Lens culinaris agglutinin A-reactive α-fetoprotein and des-γ-carboxy prothrombin as an early diagnosis of hepatocellular carcinoma in the follow-up of cirrhotic patients. Oncol Rep 2000;7:249-56.
24. Paradis V, Degos F, Dargere D, et al. Identification of a new marker of hepatocellular carcinoma by serum protein profiling of patients with chronic liver diseases. Hepatology 2005;41:40-7.
25. Poon TC, Yip TT, Chan AT, et al. Comprehensive proteomic profiling identifies serum proteomic signatures for detection of hepatocellular carcinoma and its subtypes. Clin Chem 2003;49:752-60.
26. Schwegler EE, Cazares L, Steel LF, et al. SELDI-TOF MS profiling of serum for detection of the progression of chronic hepatitis C to hepatocellular carcinoma. Hepatology 2005;41:634-42.
27. Aivado M, Spentzos D, Alterovitz G, et al. Optimization and evaluation of surface-enhanced laser desorption/ionization time-of-flight mass spectrometry (SELDI-TOF MS) with reversed-phase protein arrays for protein profiling. Clin Chem Lab Med 2005;43:133-40.
28. Lepre J, Rice JJ, Tu Y, Stolovitzky G. Genes@Work: an efficient algorithm for pattern discovery and multivariate feature selection in gene expression data. Bioinformatics 2004;20:1033-44.
29. Golub TR, Slonim DK, Tamayo P, et al. Molecular classification of cancer: class discovery and class prediction by gene expression monitoring. Science 1999;286:531-7.
30. Califano A, Stolovitzky G, Tu Y. Analysis of gene expression microarrays for phenotype classification. Proc Int Conf Intell Syst Mol Biol 2000;8:75-85.
31. Hwang D, Alevizos I, Schmitt WA, et al. Genomic dissection for characterization of cancerous oral epithelium tissues using transcription profiling. Oral Oncol 2003;39:259-68.
32. Azuaje F. Genomic data sampling and its effect on classification performance assessment. BMC Bioinformatics 2003;4:5.
33. Beer DG, Kardia SL, Huang CC, et al. Gene-expression profiles predict survival of patients with lung adenocarcinoma. Nat Med 2002;8:816-24.
34. Ambroise C, McLachlan GJ. Selection bias in gene extraction on the basis of microarray gene-expression data. Proc Natl Acad Sci U S A 2002;99:6562-6.
35. Xiao X, Liu D, Tang Y, et al. Development of proteomic patterns for detecting lung cancer. Dis Markers 2003;19:33-9.
36. Sneath PH, Sokal RR. Numerical taxonomy. Nature 1962;193:855-60.
37. The Cancer of the Liver Italian Program (CLIP) Investigators. A new prognostic system for hepatocellular carcinoma. A retrospective study of 435 patients. Hepatology 1998;28:751-5.
38. Chu SC, Wang CP, Chang YH, et al. Increased cystatin C serum concentrations in patients with hepatic diseases of various severities. Clin Chim Acta 2004;341:133-8.
39. Action Plan for Liver Disease Research. U.S. Department of Health and Human Services. NIH Publication number 04-5491, December 2004.